{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:29:20Z","timestamp":1787758160718,"version":"build-2784847793"},"reference-count":75,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Network of Excellence for Advanced Diagnosis","award":["PNC-E3-2022-23683266"],"award-info":[{"award-number":["PNC-E3-2022-23683266"]}]},{"name":"Italian Network of Excellence for Advanced Diagnosis","award":["C43C22001630001"],"award-info":[{"award-number":["C43C22001630001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Proteolysis-Targeting Chimeras (PROTACs) are heterobifunctional molecules that induce the selective degradation of a protein of interest by recruiting an E3 ubiquitin ligase, thereby triggering ubiquitination and proteasomal clearance. As part of the broader targeted protein degradation (TPD) paradigm, PROTACs offer a powerful strategy to eliminate pathogenic proteins that are difficult to modulate with traditional occupancy-based inhibitors. However, their clinical translation is often limited by poor aqueous solubility, suboptimal cellular permeability, and off-target effects. Notably, some PROTACs retain potent biological activity despite limited membrane permeability, owing to their catalytic mechanism of action, which allows even a small number of molecules reaching the target site to drive substantial protein degradation and produce important pharmacological effects. Growing evidence supports the application of PROTAC-based approaches in neurodegenerative diseases, where the selective removal of toxic or misfolded proteins is particularly attractive. This review summarizes recent advances in chemical protein degradation strategies for neurodegenerative disorders and highlights potential future perspectives of multifunctional PROTACs for therapeutic development.<\/jats:p>","DOI":"10.3390\/ph19091352","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:04:32Z","timestamp":1787756672000},"page":"1352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PROTAC-Based Strategies in Neurodegenerative Diseases: Challenges and Perspectives"],"prefix":"10.3390","volume":"19","author":[{"given":"Pasquale","family":"Degennaro","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-6265","authenticated-orcid":false,"given":"Imane","family":"Ghafir El Idrissi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-5087","authenticated-orcid":false,"given":"Rosa","family":"Purgatorio","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Fanizzi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5304-6764","authenticated-orcid":false,"given":"Mariagrazia","family":"Rullo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4198-3897","authenticated-orcid":false,"given":"Leonardo","family":"Pisani","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Macchia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Torsi","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-7972","authenticated-orcid":false,"given":"Angela","family":"Stefanachi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2043-7464","authenticated-orcid":false,"given":"Francesco","family":"Leonetti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Science, University of Bari Aldo Moro, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dur\u00e3es, F., Pinto, M., and Sousa, E. (2018). Old Drugs as New Treatments for Neurodegenerative Diseases. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020044"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein Misfolding, Aggregation, and Conformational Strains in Neurodegenerative Diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Van Bulck, M., Sierra-Magro, A., Alarcon-Gil, J., Perez-Castillo, A., and Morales-Garcia, J.A. (2019). Novel Approaches for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030719"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a Risk Factor for Neurodegenerative Disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nature20411","article-title":"Ageing, Neurodegeneration and Brain Rejuvenation","volume":"539","year":"2016","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of Neurodegenerative Diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Stroo, E., Koopman, M., Nollen, E.A.A., and Mata-Cabana, A. (2017). Cellular Regulation of Amyloid Formation in Aging and Disease. Front. Neurosci., 11.","DOI":"10.3389\/fnins.2017.00064"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/17568919.2026.2636501","article-title":"Medicinal Chemistry Approaches for Dual Inhibition of Amyloid-\u03b2 and Tau Aggregation in Alzheimer\u2019s Disease","volume":"18","author":"Jangra","year":"2026","journal-title":"Future Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How Many Drug Targets Are There?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1111\/bph.13066","article-title":"Beyond Traditional Pharmacology: New Tools and Approaches","volume":"172","author":"Gurevich","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3229","article-title":"Development Trends for Human Monoclonal Antibody Therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense Technology: An Overview and Prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","article-title":"RNA-Based Therapeutics: Current Progress and Future Prospects","volume":"19","author":"Burnett","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced Protein Degradation: An Emerging Drug Discovery Paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.181.4096.223","article-title":"Principles That Govern the Folding of Protein Chains","volume":"181","author":"Anfinsen","year":"1973","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hanley, S.E., and Cooper, K.F. (2020). Sorting Nexins in Protein Homeostasis. Cells, 10.","DOI":"10.20944\/preprints202011.0241.v1"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.chembiol.2010.05.011","article-title":"Targeting the Undruggable Proteome: The Small Molecules of My Dreams","volume":"17","author":"Crews","year":"2010","journal-title":"Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical Genetic Control of Protein Levels: Selective in vivo Targeted Degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"117297","DOI":"10.1016\/j.bcp.2025.117297","article-title":"Molecular Glues and PROTACs in Targeted Protein Degradation: Mechanisms, Advances, and Therapeutic Potential","volume":"242","author":"Eladl","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Alam, M.M., Wasim, S., and Lee, S.-Y. (2025). Emerging Concepts of Targeted Protein Degrader Technologies via Lysosomal Pathways. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125582"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric Molecules That Target Proteins to the Skp1\u2013Cullin\u2013F Box Complex for Ubiquitination and Degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted Intracellular Protein Degradation Induced by a Small Molecule: En Route to Chemical Proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a Primary Target of Thalidomide Teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel\u2013Lindau E3 Ubiquitin Ligase Using Small Molecules to Disrupt the VHL\/HIF-1\u03b1 Interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1\u2013CRBN E3 Ubiquitin Ligase in Complex with Thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ddtec.2019.02.004","article-title":"Cereblon Modulators: Low Molecular Weight Inducers of Protein Degradation","volume":"31","author":"Chamberlain","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2019.37.7_suppl.259","article-title":"ARV-110: An Oral Androgen Receptor PROTAC Degrader for Prostate Cancer","volume":"37","author":"Neklesa","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"PD13-08","DOI":"10.1158\/1538-7445.SABCS21-PD13-08","article-title":"Abstract PD13-08: First-in-Human Safety and Activity of ARV-471, a Novel PROTAC\u00ae Estrogen Receptor Degrader, in ER+\/HER2- Locally Advanced or Metastatic Breast Cancer","volume":"82","author":"Hamilton","year":"2022","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2022.40.6_suppl.017","article-title":"Phase 1\/2 Study of ARV-110, an Androgen Receptor (AR) PROTAC Degrader, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","volume":"40","author":"Gao","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"Abstract 44: The Discovery of ARV-471, an Orally Bioavailable Estrogen Receptor Degrading PROTAC for the Treatment of Patients with Breast Cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","article-title":"NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_34","unstructured":"(2026, July 07). Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson\u2019s Disease Treated for 28 Days. Available online: https:\/\/ir.arvinas.com\/news-releases\/news-release-details\/arvinas-announces-positive-phase-1-data-arv-102-showing-greater\/."},{"key":"ref_35","unstructured":"FDA (2026, July 07). FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1021\/acs.jmedchem.2c00302","article-title":"Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One","volume":"65","author":"Salerno","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed Multiple Ligands. An Emerging Drug Discovery Paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1039\/C9MD00185A","article-title":"A MedChem Toolbox for Cereblon-Directed PROTACs","volume":"10","author":"Steinebach","year":"2019","journal-title":"MedChemComm"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1021\/acs.jmedchem.6b01781","article-title":"A \u201cClick Chemistry Platform\u201d for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation","volume":"61","author":"Wurz","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between Amyloid-\u03b2 and Tau in Alzheimer\u2019s Disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"40362","DOI":"10.1039\/C7RA05347A","article-title":"Hydrophobic Tagging-Mediated Degradation of Alzheimer\u2019s Disease Related Tau","volume":"7","author":"Gao","year":"2017","journal-title":"RSC Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1002\/anie.201503720","article-title":"Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging","volume":"54","author":"Gustafson","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A Novel Small-Molecule PROTAC Selectively Promotes Tau Clearance to Improve Cognitive Functions in Alzheimer-like Models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"26308","DOI":"10.1021\/acsomega.2c02130","article-title":"Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer\u2019s Disease","volume":"7","author":"Liang","year":"2022","journal-title":"ACS Omega"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/cn300110c","article-title":"Glycogen Synthase Kinase 3 Inhibition Promotes Adult Hippocampal Neurogenesis in vitro and in vivo","volume":"3","author":"Palomo","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101496","DOI":"10.1016\/j.arr.2021.101496","article-title":"Past, Present and Future of Therapeutic Strategies against Amyloid-\u03b2 Peptides in Alzheimer\u2019s Disease: A Systematic Review","volume":"72","author":"Jeremic","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"113889","DOI":"10.1016\/j.ejmech.2021.113889","article-title":"Discovery of PT-65 as a Highly Potent and Selective Proteolysis-Targeting Chimera Degrader of GSK3 for Treating Alzheimer\u2019s Disease","volume":"226","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/acschemneuro.3c00096","article-title":"PROTAC-Induced Glycogen Synthase Kinase 3\u03b2 Degradation as a Potential Therapeutic Strategy for Alzheimer\u2019s Disease","volume":"14","author":"Guardigni","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8857","DOI":"10.1038\/s41467-025-63928-8","article-title":"Discovery of a CNS Active GSK3 Degrader Using Orthogonally Reactive Linker Screening","volume":"16","author":"Holmqvist","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-Synuclein Structure and Parkinson\u2019s Disease\u2014Lessons and Emerging Principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nan.12298","article-title":"Review: Sporadic Parkinson\u2019s Disease: Development and Distribution of \u03b1 -synuclein Pathology","volume":"42","author":"Braak","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13578-021-00709-y","article-title":"\u03b1-Synuclein-Mediated Neurodegeneration in Dementia with Lewy Bodies: The Pathobiology of a Paradox","volume":"11","author":"Simon","year":"2021","journal-title":"Cell Biosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1021\/acs.jmedchem.3c00274","article-title":"Discovery of Small-Molecule Degraders for Alpha-Synuclein Aggregates","volume":"66","author":"Tong","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41586-020-2673-2","article-title":"Structure of LRRK2 in Parkinson\u2019s Disease and Model for Microtubule Interaction","volume":"588","author":"Deniston","year":"2020","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.cell.2020.08.004","article-title":"The in situ Structure of Parkinson\u2019s Disease-Linked LRRK2","volume":"182","author":"Watanabe","year":"2020","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood\u2013Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_58","unstructured":"(2026, August 05). Available online: https:\/\/www.dcchemicals.com\/product_show-arv-102.html."},{"key":"ref_59","unstructured":"(2026, August 06). ARV-027. Available online: https:\/\/synapse.patsnap.com\/drug\/875d1240b25d4ace873c32c359e472e8?."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18661","DOI":"10.1073\/pnas.2007667117","article-title":"Site-Specific Ubiquitination of Pathogenic Huntingtin Attenuates Its Deleterious Effects","volume":"117","author":"Boulos","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1002\/anie.201706529","article-title":"Discovery of Small Molecules That Induce the Degradation of Huntingtin","volume":"56","author":"Tomoshige","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bmcl.2018.01.012","article-title":"Degradation of Huntingtin Mediated by a Hybrid Molecule Composed of IAP Antagonist Linked to Phenyldiazenyl Benzothiazole Derivative","volume":"28","author":"Tomoshige","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13024-020-00397-1","article-title":"The Role of TDP-43 Mislocalization in Amyotrophic Lateral Sclerosis","volume":"15","author":"Suk","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bioorg.2018.11.042","article-title":"TDP-43 Specific Reduction Induced by Di-Hydrophobic Tags Conjugated Peptides","volume":"84","author":"Gao","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-023-00921-7","article-title":"Degradation of Neurodegenerative Disease-Associated TDP-43 Aggregates and Oligomers via a Proteolysis-Targeting Chimera","volume":"30","author":"Tseng","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1021\/acs.jmedchem.3c01719","article-title":"Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s Disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/med.21699","article-title":"From Combinations to Multitarget-directed Ligands: A Continuum in Alzheimer\u2019s Disease Polypharmacology","volume":"41","author":"Albertini","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"104673","DOI":"10.1016\/j.drudis.2026.104673","article-title":"Medicinal Chemistry Strategies to Breach the Blood\u2013Brain Barrier: Structural Design Principles for Brain-Targeted Therapeutics","volume":"31","author":"Gupta","year":"2026","journal-title":"Drug Discov. Today"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1873-3468.15053","article-title":"A Guide for Blood\u2013Brain Barrier Models","volume":"599","author":"Soliman","year":"2025","journal-title":"FEBS Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1021\/acsmedchemlett.5c00768","article-title":"BBB-Permeable PROTACs: Where Do We Stand?","volume":"17","author":"Francisco","year":"2026","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.cell.2025.03.036","article-title":"CD36-Mediated Endocytosis of Proteolysis-Targeting Chimeras","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1038\/s41467-025-60039-2","article-title":"DNA Nanoflower Oligo-PROTAC for Targeted Degradation of FUS to Treat Neurodegenerative Diseases","volume":"16","author":"Ge","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"110045","DOI":"10.1016\/j.bioorg.2026.110045","article-title":"PROTAC Technology: Clinical Applications, Future Challenges, and Innovative Strategies","volume":"179","author":"Liu","year":"2026","journal-title":"Bioorg. Chem."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:08:22Z","timestamp":1787756902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":75,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091352"],"URL":"https:\/\/doi.org\/10.3390\/ph19091352","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}